Point72 Asset Management L.P. boosted its position in shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 768.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 101,636 shares of the company’s stock after buying an additional 89,936 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.25% of Pacira Pharmaceuticals worth $3,257,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of PCRX. Raymond James & Associates increased its holdings in Pacira Pharmaceuticals by 21.7% during the 2nd quarter. Raymond James & Associates now owns 21,611 shares of the company’s stock worth $693,000 after purchasing an additional 3,850 shares in the last quarter. BlueMountain Capital Management LLC boosted its stake in shares of Pacira Pharmaceuticals by 282.1% during the 2nd quarter. BlueMountain Capital Management LLC now owns 9,866 shares of the company’s stock worth $316,000 after buying an additional 7,284 shares during the last quarter. Stephens Investment Management Group LLC boosted its stake in shares of Pacira Pharmaceuticals by 13.9% during the 2nd quarter. Stephens Investment Management Group LLC now owns 1,198,271 shares of the company’s stock worth $37,206,000 after buying an additional 146,319 shares during the last quarter. Cortina Asset Management LLC lifted its stake in Pacira Pharmaceuticals by 25.8% in the 2nd quarter. Cortina Asset Management LLC now owns 406,050 shares of the company’s stock valued at $13,014,000 after purchasing an additional 83,229 shares during the last quarter. Finally, Mutual of America Capital Management LLC lifted its stake in Pacira Pharmaceuticals by 15.3% in the 2nd quarter. Mutual of America Capital Management LLC now owns 155,554 shares of the company’s stock valued at $4,986,000 after purchasing an additional 20,606 shares during the last quarter.

PCRX stock traded up $0.09 during midday trading on Friday, hitting $44.14. The stock had a trading volume of 450,389 shares, compared to its average volume of 834,909. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -76.10 and a beta of 1.86. The company has a quick ratio of 7.79, a current ratio of 8.58 and a debt-to-equity ratio of 0.98. Pacira Pharmaceuticals Inc has a 1-year low of $26.95 and a 1-year high of $52.60.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Thursday, August 2nd. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.37. Pacira Pharmaceuticals had a negative net margin of 3.64% and a negative return on equity of 0.39%. The business had revenue of $84.10 million for the quarter, compared to analyst estimates of $77.53 million. During the same quarter in the previous year, the business earned ($0.11) earnings per share. Pacira Pharmaceuticals’s revenue for the quarter was up 18.6% on a year-over-year basis. Research analysts expect that Pacira Pharmaceuticals Inc will post -0.21 earnings per share for the current year.

PCRX has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $48.00 price target on shares of Pacira Pharmaceuticals in a report on Tuesday, July 10th. ValuEngine raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, July 28th. Piper Jaffray Companies set a $48.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. Royal Bank of Canada set a $50.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. Finally, Needham & Company LLC raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research note on Friday, August 3rd. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $48.00.

In related news, CAO Kristen Marie Williams sold 4,773 shares of the business’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $47.04, for a total transaction of $224,521.92. Following the transaction, the chief accounting officer now directly owns 22,374 shares in the company, valued at $1,052,472.96. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark A. Kronenfeld bought 1,000 shares of the company’s stock in a transaction on Tuesday, August 28th. The stock was bought at an average price of $44.61 per share, for a total transaction of $44,610.00. Following the completion of the purchase, the director now owns 8,577 shares of the company’s stock, valued at $382,619.97. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 40,502 shares of company stock valued at $1,913,864. Insiders own 5.90% of the company’s stock.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Recommended Story: Why is the conference call important?

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.